Veru Inc. (NASDAQ: VERU), the stock kept on staying up 16.35% to $11.28 in after-market as the biotech oncology company focusing on the development of novel prostate and breast cancer management medicines, unveils positive Phase 2 clinical trial results for the selected oral, novel selective androgen receptor (AR) targeting agent enobosarm for the treatment of endocrine and chemotherapy-resistant ER+/HER2 metastatic breast cancer.
In 85% of all breast cancers, oestrogen receptor (ER) is present, and more than 90% of ER+ positive breast cancers also contain AR, which is a significant therapeutic target for ER+ breast cancer. Enobosarm is an oral drug that selectively targets AR in breast cancer without harmful side effects of unwanted virilizing androgen including facial hair, acne, hematocrit increase, or liver toxicity while having potential clinical benefits including increasing muscle and physical function as well as addressing bone loss and fractures induced by cancer treatment. Having been assessed in 25 separate research trials with 2,091 patients treated, including three Phase 2 advanced breast cancer clinical trials, Enobosarm has substantial non-clinical and clinical experience.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
As we reported yesterday, during the premarket the stock was surging following its quarterly results announcement.